Icatibant Acetate Injection shortage
Icatibant Acetate Injection is currently listed in shortage by the FDA. The FDA lists 2 affected products. This page was last refreshed from FDA data on Sep 22, 2026.
Fresenius Kabi is permanently stopping its icatibant acetate injection 10 mg/1 mL. Other makers — including Takeda, which sells the brand Firazyr (icatibant acetate) — have not reported a shortage, so the medicine is still listed as available from other sources.
Don’t stop or change your therapy on your own — talk with your prescriber about the plan that fits you, and ask your pharmacist what’s actually available (see options).
Do you take this drug? See the ‘What to do’ recommendation from Dr. Brian Staiger, PharmD →What’s in shortage — at a glance
These figures count only the manufacturers that reported this shortage to the FDA — not every company that makes Icatibant Acetate Injection. Other makers that haven’t reported a problem are shown in the green card below.
Shortage timeline
-
May 7, 2026Currently in shortage2 of 2 products affected.
-
May 7, 2026First reported to the FDA2 products first listed.
Built from FDA posting and update dates. The end date FDA publishes is the posting/update date, not a true resolution date, so durations are approximate.
What exactly is on backorder — by manufacturer
Manufacturer: Fresenius Kabi USA, LLC 📞 847-550-2300 2 NDCS click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| To Be Discontinued | Icatibant Acetate, Injection, 10 mg/1 mL (NDC 63323-574-93) | — | — | Discontinuation of the manufacturer of the drug | — |
| To Be Discontinued | Icatibant Acetate, Injection, 10 mg/1 mL (NDC 63323-574-86) | — | — | Discontinuation of the manufacturer of the drug | — |
These rows are manufacturer reports to the FDA for Icatibant Acetate Injection — they do not necessarily cover every manufacturer that makes this drug. A company appears here only if it told the FDA it has a supply problem, so other makers may still have stock. That’s the basis for the Where else can I get Icatibant Acetate Injection? options further down this page.
Why is Icatibant Acetate Injection in shortage?
Fresenius Kabi USA has reported that it is permanently stopping production of its icatibant acetate injection 10 mg/1 mL — both package versions it makes (NDC 63323-574-86 and NDC 63323-574-93) are being discontinued. The reason given is that the manufacturer itself is discontinuing production of this drug.
It's worth knowing that this report only reflects what Fresenius Kabi has filed with the FDA. No specific reason beyond the manufacturer's decision to stop making it was shared publicly, so I can't tell you more about the "why" behind that choice. Other manufacturers of icatibant may be listed separately on the FDA shortage page.
Based on the manufacturer-reported reason(s) and notes on file with the FDA for Icatibant Acetate Injection, summarized in plain English by HelloPharmacist. A drug can be short for more than one reason, and the FDA updates these as manufacturers report changes.
What should I do if I take Icatibant Acetate Injection?
Icatibant Acetate Injection is currently on the FDA drug-shortage list, and I want to walk you through what that means for you.
The only strength covered by this report is the 10 mg/1 mL injection, and it does not have an available source right now. The reason listed is that the manufacturer who filed this report, Fresenius Kabi USA, is discontinuing this product. Because this is a discontinuation rather than a temporary delay, this supply problem may be permanent for that maker, and no estimated-recovery date is given.
Even so, this report reflects only one manufacturer. The same medicine, icatibant acetate, is still on the market from other companies, so it is not gone everywhere. Here is what I suggest:
- Do not stop, skip, or change how you use this medicine on your own.
- Ask your pharmacy to check wholesalers and other manufacturers — the same medicine is available from makers such as Teva, Hikma, Takeda (Firazyr), Eugia, Alembic, Cipla, and Cycle (Sajazir), though these may not be in local stock.
- Because your current product is being discontinued, talk with your prescriber or pharmacist about a suitable alternative.
Manufacturer contact numbers are listed on this page for reference; your pharmacy usually handles those calls. This is general, national information and may not match your local pharmacy's stock.
- Don’t stop or change the medication on your own — talk to your prescriber first.
- If this is part of an ongoing or essential regimen (for example HIV treatment or prevention, seizure, heart, transplant, diabetes or mental-health medicines), do not skip or ration doses — contact your pharmacist or prescriber right away to arrange continued supply before you run out.
- Ask your pharmacy to check other manufacturers, strengths, package sizes, and nearby stores.
- Ask your prescriber whether a different strength, formulation, or the brand/generic version is appropriate.
Where else can I get Icatibant Acetate Injection?
FDA shortages are manufacturer-reported — a company only shows up on the shortage list if it told the FDA it has a supply problem, so not every maker of Icatibant Acetate Injection is necessarily short. Below we pull together the other still-marketed options that are not reported in shortage: the same medicine from manufacturers that haven’t reported a problem, and alternative dosage forms. These may still be out of stock at your pharmacy, and only your prescriber or pharmacist can decide what’s right for you.
Same medicine, other manufacturers (not reported short)
Same active ingredient, dosage form & route as the shortage (matched on the FDB HICL ingredient code), from makers that have not filed a shortage with the FDA:
| Product | Strength | Form / route | Manufacturer | NDC |
|---|---|---|---|---|
| Icatibant | ICATIBANT ACETATE 10 mg/mL | Injection, Solution · Subcutaneous | Teva Pharmaceuticals USA, Inc. | 00093-3066-34 |
| Icatibant | ICATIBANT ACETATE 30 mg/3mL | Injection, Solution · Subcutaneous | Hikma Pharmaceuticals USA Inc. | 24201-0207-01 |
| Firazyr | ICATIBANT ACETATE 30 mg/3mL | Injection, Solution · Subcutaneous | Takeda Pharmaceuticals America, Inc. | 54092-0702-01 |
| Icatibant | ICATIBANT ACETATE 30 mg/3mL | Injection, Solution · Subcutaneous | Eugia US LLC | 55150-0351-01 |
| Icatibant | ICATIBANT ACETATE 30 mg/3mL | Injection · Subcutaneous | Alembic Pharmaceuticals Inc. | 62332-0654-03 |
| Icatibant | ICATIBANT ACETATE 30 mg/3mL | Injection · Subcutaneous | Cipla USA Inc. | 69097-0664-34 |
| Sajazir | ICATIBANT ACETATE 30 mg/3mL | Injection · Subcutaneous | Cycle Pharmaceuticals Ltd-Uk | 70709-0013-01 |
Therapeutic equivalents & pricing 10 productsclick to expand
Orange Book–rated equivalents of the affected strengths, with the latest NADAC price (a federal retail-acquisition benchmark, not your copay) and an evidence-based availability label. Cheapest first.
| Product | Manufacturer | Package | NADAC $/unit | AB rating | Availability |
|---|---|---|---|---|---|
| Icatibant 10 mg/mL | Teva | 1 syringe | — | AP | FDA listed |
| Icatibant 30 mg/3mL | Hikma | 1 syringe | — | AP | FDA listed |
| Icatibant 30 mg/3mL | Alembic | 1 syringe | — | AP | FDA listed |
| Firazyr 30 mg/3mL | Takeda | 1 syringe | — | AP | FDA listed |
| Icatibant 30 mg/3mL | Eugia | 1 syringe | — | AP | FDA listed |
| Icatibant 30 mg/3mL | Alembic | 1 syringe | — | AP | FDA listed |
| Icatibant 10 mg/mL | Fresenius | 1 syringe | — | AP | FDA listed |
| Icatibant 30 mg/3mL | Cipla | 1 syringe | — | AP | FDA listed |
| Sajazir 30 mg/3mL | Cycle | 1 syringe | — | AP | FDA listed |
| Icatibant 10 mg/mL | Fresenius | 1 syringe | — | AP | FDA listed |
Equivalents share the same ingredient, strength, dosage form and route; an AB rating means the FDA considers them substitutable. NADAC is a national retail-pharmacy acquisition benchmark from CMS — not what you pay. Availability is inferred from recent pricing, not a stock check.
Identity & classification
Where does this data come from?
Other hematology shortages
Icatibant Acetate Injection shortage FAQs
Is Icatibant Acetate Injection in shortage?
Which products are affected?
When will Icatibant Acetate Injection be available again?
Can I still get Icatibant Acetate somewhere?
What should I do if I take Icatibant Acetate Injection?
Still have a question about the Icatibant Acetate Injection shortage?
Ask a pharmacist about this shortage →View Icatibant Acetate Injection on the FDA drug-shortage database →
Where does this data come from?
/drug/shortages) — drug, manufacturer & contact, NDC/product, status, availability, reason, therapeutic category and posting/update dates. Current / To Be Discontinued = active; Resolved is kept for history. The Supply-Risk rating is assessed per active ingredient and adds the FDA NDC Directory (still-marketed manufacturers by ingredient & form); same-medicine and equivalent products use First Databank classification + CMS NADAC pricing; Medicaid use + most-affected states come from CMS Medicaid State Drug Utilization Data. Reference only — confirm current status with the manufacturer or FDA before acting on it.